Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis
Ended Project Grant Awarded Last action
- Award ID
- R43AR073541
- Recipient
-
Reveragen Biopharma, Inc. UEI NQA4J3L3E1Z4
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $178,041
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date
- Originally
- Place of performance
- Rockville, MD 20850, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $178,041 |
Quick answers
Who received award R43AR073541?
R43AR073541 was awarded to Reveragen Biopharma, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on June 1, 2018.
How much is award R43AR073541 worth?
$178,041 has been obligated on R43AR073541.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award